What is the dead-space loss per draw with a 29G needle at 4 mg/mL?

The specifics, since they change the answer: a 29G needle · 4 mg/mL.

I would rather understand the derivation than memorise the outcome.

Two people I asked gave two answers that differ by a factor of ten, which is suggestive.

Can someone show the working rather than just the answer?

Concretely, dead space is the volume trapped in the syringe hub and needle after the plunger bottoms out, and it is the reason your 10 mg vial yields only 9.5 mg of usable draws.

Dead space quantified: a fixed-needle insulin syringe holds roughly 3 to 5 µL in the hub and needle after the plunger bottoms out. A luer-lock syringe with a detachable needle holds 35 to 100 µL depending on the hub design.

In practice, low-dead-space syringe designs either have the needle bonded directly to the barrel — a fixed-needle syringe, which is the cheapest route — or add a moulded projection on the plunger tip that fills the luer cone.

Worth noting: draw size matters enormously — the smaller your draws, the more the syringe architecture matters.

Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.

The switch to a low-dead-space syringe nearly doubles your usable vial, which is better than switching suppliers if you are looking for cost savings.

At 5 mg/mL that is 15 to 25 µg lost per draw on the insulin syringe and 175 to 500 µg on the luer-lock — which over ten draws is the difference between losing a rounding error and losing half a milligram.

It helps to be literal here: the needle lumen volume is under a microlitre in a typical fine-gauge configuration, so the needle is not the problem.

Syringe residual volume has been measured properly, mainly in the infection-control literature, with a median residual of about 84 µL for a conventional 1 mL syringe with a detachable needle and roughly 2 µL for a fixed-needle low-dead-space design.

If cost matters, this is the first thing to change, not the last.

This is arithmetic, so let us do the arithmetic and see where the losses actually are.

Draws available = 2000 / 102 = 19.6, so 19 full draws. Delivered peptide = 19 x 0.5 mg = 9.5 mg. Lost to dead space = 19 x 2 µL = 38 µL x 0.005 = 0.19 mg. Yield = 95 per cent.

Be sceptical of anything advertised as low dead space that retains a conventional plunger tip: if you can look into the fitting with the plunger fully forward and see an open conical void, that void is your dead space.

Published inter-laboratory comparisons of dead-space measurements on identical syringes show good agreement, suggesting the numbers are reliable.

One qualification: the dead space does not affect the dose accuracy if the hub was full of solution at the start of the draw.

The switch nearly doubles your vial, which is better than most other optimisations combined.

Stated carefully, dead space is irreducible with a high-dead-space syringe, which is why the hardware matters more than any technique.

Configuration B — 0.5 mL fixed-needle U-100 insulin syringe, dead space 2 µL: volume removed per draw = 100 + 2 = 102 µL.

The World Health Organisation guidance on injection equipment adopted the same high-versus-low dead-space distinction, using a low-dead-space threshold in the low single-digit microlitres.

I would not underestimate the dead-space cost when calculating your true cost per dose.

Buy the right syringe — a fixed-needle insulin syringe is cheap and solves the problem.

edited 9 Dec 2025 by v_ramaswamy — expanded the table to cover the lower concentration

Start from the worked arithmetic: a 10 mg vial reconstituted with 2 mL gives 5 mg/mL. One hundred microliter draws are 0.5 mg each. At 84 µL dead space per draw, half your vial disappears into the hub.

The luer cone of the syringe plus the needle's own plastic hub accounts for the vast majority of the dead space.

Syringe residual volume has been measured properly, mainly in the infection-control literature, with a median residual of about 84 µL for a conventional 1 mL syringe with a detachable needle and roughly 2 µL for a fixed-needle low-dead-space design.

If cost matters, this is the first thing to change, not the last.

edited 23 Oct 2025 by t_oyelaran — added the placebo-arm figures